Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 5Prostatic Neoplasms 3Colorectal Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Hemangiosarcoma 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

balstilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) × balstilimab × Clear all
NCT06589440 2026-01-15

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Stingray Therapeutics

Phase 2 Recruiting
70 enrolled
Gastrointestinal

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡